We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

SD BIOSENSOR

SD BIOSENSOR develops immunological and molecular diagnostics and blood glucose self-monitoring systems, glycated hem... read more Featured Products: More products

Download Mobile App




Point-of-Care Diagnostic to Identify G6PD Deficiency Evaluated

By LabMedica International staff writers
Posted on 31 Aug 2021
Print article
Image: The STANDARD G6PD Test is a handheld device that delivers results in two minutes and provides a quantitative measure of G6PD activity, including in heterozygous women (Photo courtesy of SD BIOSENSOR/PATH)
Image: The STANDARD G6PD Test is a handheld device that delivers results in two minutes and provides a quantitative measure of G6PD activity, including in heterozygous women (Photo courtesy of SD BIOSENSOR/PATH)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited condition in which patients are excessively susceptible to the development of hemolytic anemia. Affected people lack the ability to tolerate biochemical oxidative stress, and red cell hemolysis is the most important clinical consequence.

People with G6PD deficiency are at risk of hemolysis when exposed to certain medications, including 8-aminoquinoline drugs used to treat Plasmodium vivax malaria. The diagnosis of G6PD deficiency is made by a quantitative spectrophotometric analysis or, more commonly, by a rapid fluorescent spot test detecting the generation of NADPH from NADP. The test is positive if the blood spot fails to fluoresce under ultraviolet light.

Scientists specializing in Tropical Medicine from the Amazonas State University (Manaus, Brazil) and their international colleagues collected venous samples were from 1,662 participants, and capillary samples were available from 1,693 participants. Microscopic examinations of thick blood slides were conducted to determine malaria diagnosis. The performance of the semi-quantitative point-of-care G6PD test, STANDARD G6PD Test (SD Biosensor, Suwon, Republic of Korea). Both capillary and venous specimens were compared to matching G6PD values from venous specimens tested with a spectrophotometric reference assay normalized by hemoglobin.

The quantitative G6PD reference assay was run in duplicate using the Pointe Scientific reagent kit (Pointe Scientific, Canton, MI, USA) on a Shimadzu UV-1800 six-cell temperature-regulated manual spectrophotometer (Kyoto, Japan). Each specimen was also tested using the Trinity qualitative G6PD FST kit (G-6-PDH Screen by Spot Test, Trinity Biotech, Bray, Ireland). Hemoglobin concentration was determined within 24 hours using a KX-21N automated hematology analyzer (Sysmex, Kobe, Japan) and the HemoCue 201+ test (HemoCue AB, Ångelholm, Sweden) and run on aliquoted venous blood in the laboratory within 24 hours of sample collection.

The scientists reported that in comparison to spectrophotometry, the STANDARD G6PD Test performed equivalently in determining G6PD status in venous and capillary specimens under varied operating temperatures. Using the manufacturer-recommended reference value thresholds, the test’s sensitivity at the <30% threshold on both specimen types was 100%. Specificity was 98.6% on venous specimens and 97.8% on capillary. At the 70% threshold, the test’s sensitivity was 96.9% on venous specimens and 94.3% on capillary. Specificity was 96.5% and 92.3% on venous and capillary specimens, respectively.

The authors concluded that their data showed that the STANDARD G6PD Test performed well in comparison to the spectrophotometric reference standard. The STANDARD G6PD Test is a promising tool to aid in the identification of G6PD deficiency in Brazil. The availability of this test represents an important opportunity to improve management of P. vivax malaria cases in resource-limited settings, where reliable alternatives to quantitative spectrophotometry are needed to expand access to radical cure. The study was published on August 12, 2021 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Amazonas State University
SD Biosensor
Pointe Scientific
Shimadzu
Trinity Biotech
HemoCue AB


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Aspergillus Test
REALQUALITY Aspergillus

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.